Literature DB >> 29214570

Data Quality in Rare Diseases Registries.

Yllka Kodra1, Manuel Posada de la Paz2, Alessio Coi3, Michele Santoro3, Fabrizio Bianchi3, Faisal Ahmed4, Yaffa R Rubinstein5, Jérôme Weinbach6, Domenica Taruscio7.   

Abstract

In the field of rare diseases, registries are considered power tool to develop clinical research, to facilitate the planning of appropriate clinical trials, to improve patient care and healthcare planning. Therefore high quality data of rare diseases registries is considered to be one of the most important element in the establishment and maintenance of a registry. Data quality can be defined as the totality of features and characteristics of data set that bear on its ability to satisfy the needs that result from the intended use of the data. In the context of registries, the 'product' is data, and quality refers to data quality, meaning that the data coming into the registry have been validated, and ready for use for analysis and research. Determining the quality of data is possible through data assessment against a number of dimensions: completeness, validity; coherence and comparability; accessibility; usefulness; timeliness; prevention of duplicate records. Many others factors may influence the quality of a registry: development of standardized Case Report Form and security/safety controls of informatics infrastructure. With the growing number of rare diseases registries being established, there is a need to develop a quality validation process to evaluate the quality of each registry. A clear description of the registry is the first step when assessing data quality or the registry evaluation system. Here we report a template as a guide for helping registry owners to describe their registry.

Entities:  

Keywords:  Clinical research registry; Data quality indicators; Public health registry; Quality assurance plan; Rare diseases registries; Validity

Mesh:

Year:  2017        PMID: 29214570     DOI: 10.1007/978-3-319-67144-4_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  21 in total

1.  Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.

Authors:  James A Feinstein; Purevsuren Jambal; Kathleen Peoples; Anne W Lucky; Phuong Khuu; Jean Y Tang; Irene Lara-Corrales; Elena Pope; Karen Wiss; Kristen P Hook; Laura E Levin; Kimberly D Morel; Amy S Paller; Catherine C McCuaig; Julie Powell; Lawrence F Eichenfield; Harper Price; Moise L Levy; Lawrence A Schachner; John C Browning; Susan Bayliss; Marla Jahnke; Tor Shwayder; Sharon A Glick; Anna L Bruckner
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

2.  Accuracy and agreement of national spine register data for 474 patients compared to corresponding electronic patient records.

Authors:  Ole Kristian Alhaug; Simran Kaur; Filip Dolatowski; Milada Cvancarova Småstuen; Tore K Solberg; Greger Lønne
Journal:  Eur Spine J       Date:  2022-01-06       Impact factor: 3.134

Review 3.  Artificial intelligence and spine imaging: limitations, regulatory issues and future direction.

Authors:  Alexander L Hornung; Christopher M Hornung; G Michael Mallow; J Nicolas Barajas; Alejandro A Espinoza Orías; Fabio Galbusera; Hans-Joachim Wilke; Matthew Colman; Frank M Phillips; Howard S An; Dino Samartzis
Journal:  Eur Spine J       Date:  2022-01-27       Impact factor: 2.721

4.  Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry.

Authors:  Victoria K Shanmugam; Tracy M Frech; Virginia D Steen; Laura K Hummers; Ami A Shah; Elana J Bernstein; Dinesh Khanna; Jessica K Gordon; Flavia V Castelino; Lorinda Chung; Faye N Hant; Emily Startup; John M VanBuren; Luke B Evnin; Shervin Assassi
Journal:  Clin Rheumatol       Date:  2019-10-30       Impact factor: 2.980

Review 5.  The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review.

Authors:  Christina Q Nguyen; Kristine Alba-Concepcion; Elizabeth E Palmer; Jackie L Scully; Nicole Millis; Michelle A Farrar
Journal:  Orphanet J Rare Dis       Date:  2022-04-18       Impact factor: 4.303

6.  International Comparison of Thalassemia Registries: Challenges and Opportunities.

Authors:  Tayebeh Noori; Marjan Ghazisaeedi; Ghasem Miri Aliabad; Yousef Mehdipour; Esmaeil Mehraeen; Rosa Conte; Reza Safdari
Journal:  Acta Inform Med       Date:  2019-03

7.  The current landscape of European registries for rare endocrine conditions.

Authors:  S R Ali; J Bryce; M Cools; M Korbonits; J G Beun; D Taruscio; T Danne; M Dattani; O M Dekkers; A Linglart; I Netchine; A Nordenstrom; A Patocs; L Persani; N Reisch; A Smyth; Z Sumnik; W E Visser; O Hiort; A M Pereira; S F Ahmed
Journal:  Eur J Endocrinol       Date:  2019-01-01       Impact factor: 6.664

8.  National platform for Rare Diseases Data Registry of Japan.

Authors:  Yoshihiko Furusawa; Izumi Yamaguchi; Naoko Yagishita; Kazumasa Tanzawa; Fumihiko Matsuda; Yoshihisa Yamano
Journal:  Learn Health Syst       Date:  2019-01-31

Review 9.  Establishing Patient Registries for Rare Diseases: Rationale and Challenges.

Authors:  Vanessa Boulanger; Marissa Schlemmer; Suzanne Rossov; Allison Seebald; Pamela Gavin
Journal:  Pharmaceut Med       Date:  2020-06

10.  Recommendations for Improving the Quality of Rare Disease Registries.

Authors:  Yllka Kodra; Jérôme Weinbach; Manuel Posada-de-la-Paz; Alessio Coi; S Lydie Lemonnier; David van Enckevort; Marco Roos; Annika Jacobsen; Ronald Cornet; S Faisal Ahmed; Virginie Bros-Facer; Veronica Popa; Marieke Van Meel; Daniel Renault; Rainald von Gizycki; Michele Santoro; Paul Landais; Paola Torreri; Claudio Carta; Deborah Mascalzoni; Sabina Gainotti; Estrella Lopez; Anna Ambrosini; Heimo Müller; Robert Reis; Fabrizio Bianchi; Yaffa R Rubinstein; Hanns Lochmüller; Domenica Taruscio
Journal:  Int J Environ Res Public Health       Date:  2018-08-03       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.